Exploring the biological basis of haemophilic joint disease: Experimental studies

Haemophilia

Volumn 18, Issue 3, 2012, Pages 310-318

  Valentino, L A ^a   Hakobyan, N ^a   Enockson, C ^a   Simpson, M L ^a   Kakodkar, N C ^a   Cong, L ^a   Song, X ^a  

^a Rush Children's Hospital and Rush University Medical Center   (United States)

Author keywords

Arthropathy; Blood; Haemarthrosis; Haemophilia; Joint; Synovitis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BONE MORPHOGENETIC PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN;

ARTHROPATHY; BONE MALFORMATION; CELL PROLIFERATION; DISEASE SEVERITY; ERYTHEMA; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIC ARTHROPATHY; HUMAN; INNATE IMMUNITY; JOINT STIFFNESS; JOINT SWELLING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SYNOVITIS;

ANIMALS; ANTICOAGULANTS; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; JOINT DISEASES; MICE; MODELS, MOLECULAR; PHENOTYPE; SYNOVITIS;

EID: 84860344129     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02669.x     Document Type: Review

References (113)

1. Mannucci PM. Ham-wasserman lecture: hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 2002; 1-9.
2. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
3. Rydin E, Lundberg PO. Letter: tranexamic acid and intracranial thrombosis. Lancet 1976; 2: 49.
4. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158(Suppl 3): S166-70.
5. Stein H, Duthie RB. The pathogenesis of chronic haemophilic arthropathy. J Bone Joint Surg Br 1981; 63B: 601-9.
6. Valentino LA, Hakobyan N, Rodriguez N, Hoots WK. Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage. Haemophilia 2007; 13(Suppl 3): 10-3.
7. Pergantou H, Matsinos G, Papadopoulos A, Platokouki H, Aronis S. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12(3): 241-7.
8. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
9. Hoots WK, Rodriguez N, Boggio L, Valentino LA. Pathogenesis of haemophilic synovitis: clinical aspects. Haemophilia 2007; 13(Suppl 3): 4-9.
10. Gilbert MS. Musculoskeletal complications of hemophilia: The joint. Montreal: World Federation of Hemophilia, 1997.
11. Swanton MC. Hemophilic arthropathy in dogs. Lab Invest 1959; 8: 1269-77.
12. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008; 14: 804-9.
13. Aronstam A, Wassef M, Hamad Z, McLellan DS. The effect of bleeding patterns on the response of haemophilic haemarthroses to different doses of factor VIII. Clin Lab Haematol 1981; 3: 107-12.
14. Roosendaal G, TeKoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum 1999; 42: 1033-9.
15. Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia 2005; 11: 227-32.
16. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
17. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 5 May 2011 [Epub ahead of print].
18. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2011; 4 May 2011 [Epub ahead of print].
19. De La Corte-Rodriguez H, Rodriguez-Merchan EC, Jimenez-Yuste V. Radiosynovectomy in hemophilia: quantification of its effectiveness through the assessment of 10 articular parameters. J Thromb Haemost 2011; 9: 928-35.
20. Decker JL, Malone DG, Haraoui B et al. NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Annals Intern Med 1984; 101: 810-24.
21. Klimiuk PA, Goronzy JJ, Bjor nsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151: 1311-9.
22. Furuhashi I, Abe K, Sato T, Inoue H. Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1. J Pharmacol Sci 2008; 108: 104-11.
23. Shin H, Nakajima T, Kitajima I et al. Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. Clin Immunol Immunopathol. 1995; 76(3 Pt 1): 225-33.
24. Huber R, Hummert C, Gausmann U et al. Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther 2008; 10: R98.
25. Rountree RB, Schoor M, Chen H et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol 2004; 2: e355.
26. Alsaleh G, Sparsa L, Chatelus E et al. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R135.
27. Maciejewska Rodrigues H, Jungel A, Gay RE, Gay S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol 2009; 47: 12-8.
28. Sharif SA, Du X, Myles T et al. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2902-12.
29. Quayle JA, Adams S, Bucknall RC, Edwards SW. Cytokine expression by inflammatory neutrophils. FEMS Immunol Med Microbiol 1994; 8: 233-9.
30. Cascao R, Moura RA, Perpetuo I et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 2010; 12: R196.
31. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
32. Barsante MM, Cunha TM, Allegretti M et al. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br J Pharmacol 2008; 153: 992-1002.
33. Pinto LG, Cunha TM, Vieira SM et al. IL-17 mediates articular hypernociception in antigen-induced arthritis in mice. Pain 2010; 148: 247-56.
34. Wen FQ, Jabbar AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002; 100: 912-6.
35. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004; 104: 2060-4.
36. Akhavani MA, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog EM. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11: R64.
37. Bosco MC, Delfino S, Ferlito F et al. The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis. J Rheumatol 2009; 36: 1318-29.
38. Clavel G, Bessis N, Lemeiter D et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007; 124: 158-64.
39. Dhaouadi T, Sfar I, Abelmoula L et al. Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review. Tunis Med 2007; 85: 991-8.
40. Giatromanolaki A, Sivridis E, Maltezos E et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5: R193-201.
41. Murata M, Yudoh K, Masuko K. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis Cartilage 2008; 16: 279-86.
42. Paleolog EM, Miotla JM. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 1998; 2: 295-307.
43. Wu H, Khanna D, Park G et al. Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis Rheum 2004; 50: 3093-103.
44. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002; 61(Suppl 2): ii84-6.
45. Grcevic D, Jajic Z, Kovacic N et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010; 37: 246-56.
46. Walsh NC, Reinwald S, Manning CA et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009; 24: 1572-85.
47. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
48. Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 2006; 12: 128-32.
49. Astermark J, Altisent C, Batorova A et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
50. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
51. Rullier A, Trimoulet P, Neau D et al. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol 2004; 35: 1088-94.
52. Liu B, Woltman AM, Janssen HL, Boonstra A. Modulation of dendritic cell function by persistent viruses. J Leukoc Biol 2009; 85: 205-14.
53. Kenet G, Stenmo CB, Blemings A et al. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 351-9.
54. Fox AD, Whiteley MS. Use of ultrasound in positioning a catheter for thrombolysis of an occluded prosthetic femoropopliteal graft. Clin Radiol 1995; 50: 134.
55. Escuriola Ettingshausen C, Halimeh S, Kurnik K et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
56. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010; 125: 119-23.
57. Franchini M, Montagnana M, Targher G et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009; 35: 307-12.
58. Lee DH, Walker IR, Teitel J et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83: 387-91.
59. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92: 305-10.
60. Miesbach W, Seifried E. Does haemophilia influence cancer-related mortality in HIV-negative patients? Haemophilia 2011; 17: 55-60.
61. Grunewald M, Siegemund A, Grunewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8: 768-75.
62. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008; 34: 128-41.
63. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
64. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
65. Valentino LA, Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev 2011; 25: 11-5.
66. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
67. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
68. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-7.
69. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia 2006; 12: 654-62.
70. Ovlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost 2008; 6: 969-75.
71. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
72. Roosendaal G, Mauser-Bunschoten EP, De Kleijn P et al. Synovium in haemophilic arthropathy. Haemophilia 1998; 4: 502-5.
73. Parsons JR, Zingler BM, McKeon JJ. Mechanical and histological studies of acute joint hemorrhage. Orthopedics 1987; 10: 1019-26.
74. Nishiya K. Stimulation of human synovial cell DNA synthesis by iron. J Rheumatol 1994; 21: 1802-7.
75. Bernardi F, Marchetti G, Dolce A, Mariani G. How to evaluate phenotype-genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency. Haemophilia 2004; 10(Suppl 4): 177-9.
76. Sharathkumar A, Hardesty B, Greist A et al. Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation. Haemophilia 2009; 15: 91-100.
77. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 83-92.
78. van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007; 5(Suppl 1): 151-6.
79. Yee DL. Platelets as modifiers of clinical phenotype in hemophilia. Sci World J 2006; 6: 661-8.
80. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108-17.
81. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331-4.
82. Ramstrom S, Oberg KV, Akerstrom F, Enstrom C, Lindahl TL. Platelet PAR1 receptor density - correlation to platelet activation response and changes in exposure after platelet activation. Thrombo Res 2008; 121: 681-8.
83. Huzoor A, Dean T, Kornhauser R. Increased platelet reactivity to prostaglandin E1 in hypertension is linked with altered signal transduction. Am J Hypertens 1993; 6: 857-62.
84. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-8.
85. Schlachterman A, Schuettrumpf J, Liu JH et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005; 3: 2730-7.
86. Koenderman JS, Bertina RM, Reitsma PH, de Visser MC. Factor IX-R338L (factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. Thromb Res 2011; 30 July 2011 [Epub ahead of print].
87. Simioni P, Tormene D, Tognin G et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 22: 361.
88. Mosnier LO. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem 2011; 7: 286.
89. Lind M, Boman K, Johansson L et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med 2009; 169: 1210-5.
90. Mokhtar GM, Matter RM, Shawki H, Abdel Aziz MM. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia. Pediatr Hematol Oncol 2010; 27: 363-73.
91. Zhang WL, Sun K, Wang YB et al. Association of variants in the vascular endothelial growth factor receptor 2 gene and the risk of hemorrhagic stroke. Zhonghua Yi Xue Za Zhi 2009; 89: 1536-9.
92. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
93. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
94. Lotz MK, Kraus VB. New developments in osteoarthritis. Post-traumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther 2010; 12: 211.
95. Hooiveld M, Roosendaal G, Vianen M, van den Berg M, Bijlsma J, Lafeber F. Blood-induced joint damage: longterm effects in vitro and in vivo. J Rheumatol 2003; 30: 339-44.
96. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
97. Dunn AL, Abshire TC. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol 2006; 115: 162-71.
98. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
99. Roosendaal G, Tekoppele JM, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatol 2000; 27: 1740-4.
100. Kavakli K, Yesilipek A, Antmen B et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia 2010; 16: 487-94.
101. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
102. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S45-9.
103. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
104. Banta JV, Boone DC, Smith CF. Arthrocentesis of the knee in acute hemophilic arthropathy. West J Med 1975; 122: 285-8.
105. Ingram GI, Mathews JA, Bennett AE. A controlled trial of joint aspiration in acute haemophilic haemarthrosis. Br J Haematol 1972; 23: 649-54.
106. Ingram GI, Mathews JA, Bennett AE. Controlled trial of joint aspiration in acute haemophilic haemarthrosis. Ann Rheum Dis 1972; 31: 423.
107. d'Young AI. Domiciliary application of CryoCuff in severe haemophilia: qualitative questionnaire and clinical audit. Haemophilia 2008; 14: 823-7.
108. Hermans C, P DEM, Fischer K et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
109. Muller S, Kurth AA, Hovy L. Conservative management of hemophilic arthropathy. Orthopade 1999; 28: 347-55.
110. Ribbans WJ, Giangrande P, Beeton K. Conservative treatment of hemarthrosis for prevention of hemophilic synovitis. Clin Orthop Relat Res 1997; 12-8.
111. Mejia-Carvajal C, Hakobyan N, Enockson C, Valentino LA. The impact of joint bleeding and synovitis on physical ability and joint function in a murine model of haemophilic synovitis. Haemophilia 2008; 14: 119-26.
112. Valentino LA, Kapoor M. Central venous access devices in patients with hemophilia. Expert Rev Med Devices 2005; 2: 699-711.
113. Jansen NW, Roosendaal G, Lundin B et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009; 60: 290-8.